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Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is caused by mutations in
the MAPT gene, encoding the tau protein that accumulates in intraneuronal lesions in a number of neurode-
generative diseases. Several FTDP-17 mutations affect alternative splicing and result in excess exon 10 (E10)
inclusion in tau mRNA. RNA reprogramming using spliceosome-mediated RNA trans-splicing (SMaRT) could
be a method of choice to correct aberrant E10 splicing resulting from FTDP-17 mutations. SMaRT creates
a hybrid mRNA through a trans-splicing reaction between an endogenous target pre-mRNA and a pre-
trans-splicing RNA molecule (PTM). However, FTDP-17 mutations affect the strength of cis-splicing elements
and could favor cis-splicing over trans-splicing. Excess E10 inclusion in FTDP-17 can be caused by intronic
mutations destabilizing a stem-loop protecting the 50 splice site at the E10/intron 10 junction. COS cells trans-
fected with a minigene containing the intronic 114 mutation produce exclusively E10
1 RNA. Generation of
E10
2 RNA was restored after co-transfection with a PTM designed to exclude E10. Similar results were
obtained with a target containing the exonic N279K mutation which strengthens a splicing enhancer within
E10. Conversely, increase or decrease in E10 content was achieved by trans-splicing from a target carrying
the D280K mutation, which weakens the same splicing enhancer. Thus E10 inclusion can be modulated by
trans-splicing irrespective of the strength of the cis-splicing elements affected by FTDP-17 mutations. In con-
clusion, RNA trans-splicing could provide the basis of therapeutic strategies for impaired alternative splicing
caused by pathogenic mutations in cis-acting splicing elements.
INTRODUCTION
Tauopathies are major diseases of the central nervous system
characterized neuropathologically by intracellular ﬁlamentous
inclusions formed by the microtubule-associated protein tau in
affected neurons (1,2). Tauopathies include dementias such as
Alzheimer’s disease and some forms of frontotemporal
dementia (3). Deﬁnitive evidence for the pathogenic impor-
tance of tau was provided by the discovery of dominant
mutations in the MAPT gene, the gene encoding tau, in the
rare dementia, frontotemporal dementia with parkinsonism
linked to chromosome 17 (FTDP-17) (4–6).
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splicing of exons 2, 3 and 10 generates six isoforms in the
brain. Exon 10 (E10) encodes the second of four imperfect
31–32 amino-acid microtubule-binding repeats in the
C-terminal half of the protein. Exclusion or inclusion of E10
generate tau isoforms with three (3R tau, E10
2) or four (4R
tau, E10
þ) microtubule-binding repeats, the latter having an
increased afﬁnity for microtubules. E10 is expressed only in
adults and E10
þ and E10
2 isoforms are expressed in approxi-
mately equal amounts in adult human brain.
To date, more than thirty-ﬁve MAPT mutations have been
associated with FTDP-17. Most missense mutations reduce
the afﬁnity of tau for microtubules (7), whereas silent or intro-
nic mutations affect E10 splicing and can result in an up to
6-fold excess of tau mRNA containing E10 and in an elevated
4R/3R ratio (4,6,8,9). Elevated 4R/3R ratio is likely to have
functional consequences, for example in the regulation of
axonal transport (10).
From a therapeutic perspective, correcting defective alterna-
tive splicing is best achieved by direct intervention at the RNA
level. RNA can be reprogrammed by using spliceosome-
mediated RNA trans-splicing (SMaRT
w) (11). SMaRT
creates a hybrid mRNA through a trans-splicing reaction
mediated by the spliceosome between the 50 splice site of an
endogenous target pre-mRNA and the 30 splice site of an
exogenously delivered pre-trans-splicing RNA molecule
(PTM). Conversely, a PTM can be designed to carry the 50
splice site and trans-splice to the 30 splice site of a speciﬁc
target (12). A typical application of SMaRT is the correction
of loss-of-function mutations. We have shown previously
that E10
2 to E10
þ tau RNA conversion could be achieved
using SMaRT (13). Thus, SMaRT could be a method of
choice to correct aberrant E10 splicing resulting from
FTDP-17 mutations. However, FTDP-17 mutations affect the
strength of cis-splicing elements and could favor cis-splicing
over trans-splicing. For instance, most intronic mutations are
clustered at the exon 10-intron 10 junction and disrupt a stem-
loop structure protecting the 50 splice site (14,15). Further-
more, with the exception of the P301L/S mutations, mutations
within E10 are located in cis-acting splicing regulatory
elements and promote E10 retention (16,17). We therefore
addressed the question of the potential effectiveness of
SMaRT to correct aberrant E10 splicing caused by FTDP-17
mutations. Here we show that elevated or reduced E10
inclusion caused by intronic or exonic FTDP-17 mutations
can be reversed by trans-splicing. Hence, RNA trans-splicing
could provide the basis for the development of promising
therapeutic strategies for impaired alternative splicing,
especially in the context of neurological diseases.
RESULTS
Tau PTM constructs
We have shown previously that E10 could be introduced in tau
RNA by SMaRT (13). We have now designed a PTM,
TauPTM9, to exclude E10. TauPTM9 comprises a binding
domain hybridizing with the 30 end of intron 9 and human
tau exons 11–13 followed by a FLAG epitope sequence in
the coding sequence (Fig. 1). COS cells were co-transfected
with TauPTM9 and the LI9/LI10 tau minigene consisting of
the full genomic MAPT sequence from exon 9 to exon 11,
Figure 1. Structure of TauPTM6 and TauPTM9 and resulting trans-spliced products. The coding sequence of TauPTM6 and TauPTM9 consists of exons 10–13
or exons 11–13, respectively, followed by a 24 nt FLAG epitope sequence. The trans-splicing domain of the PTMs comprises a 125 nt binding domain (BD)
complementary to the 30 end of tau intron 9 as well as a strong conserved yeast branch point sequence (BP), a 26 nt polypyrimidine tract (PPT), an AG acceptor
site and a spacer sequence separating the binding domain and the branch point. Arrows indicate the locations of the PCR primers used to detect cis- and trans-
splicing events.
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As a positive control, cells were also co-transfected with the
minigene and TauPTM6, designed to introduce E10 in tau
RNA (13). To detect trans-spliced products, RNA was ana-
lyzed by RT–PCR with a minigene-speciﬁc forward primer,
VctF, corresponding to a pCIneo vector sequence, and the
PTM-speciﬁc reverse primer, FLAGR, complementary to the
FLAG epitope sequence. Using this primer combination, a
product of 773 bp was detected in cells transfected with
TauPTM9 (Fig. 2A). Trans-splicing was also detected in
cells transfected with the minigene and TauPTM6, that has
the same binding and trans-splicing domains as TauPTM9.
The 93 bp difference in size between the TauPTM6 (866 bp)
and TauPTM9 products correspond to E10 (Fig. 2A). Sequen-
cing of VctF-FLAGR products conﬁrmed that exact exon 9–
exon 10 and exon 9–exon 11 junctions had been generated
using TauPTM6 and TauPTM9, respectively, and demon-
strates that trans-splicing has occurred between minigene tran-
scripts and either PTM.
We next analyzed whether trans-splicing with TauPTM9
was accompanied by a reduction in E10 inclusion in the
total mature RNA (i.e. cis-spliced and trans-spliced) derived
from LI9/LI10. Reverse transcribed RNA was ampliﬁed with
the VctF primer, as above, and the reverse primer 11R comp-
lementary to an exon 11 sequence, that detects both cis- and
trans-spliced products. Co-transfection of LI9/LI10 with
TauPTM9 resulted in a decrease in E10 inclusion (Fig. 2B).
Conversely, and as reported previously (13), co-transfection
Figure 2. Trans-splicing modulation of E10 usage in tau transcripts. COS cells
were co-transfected with the LI9/LI10 minigene and TauPTM6 or TauPTM9.
(A) RT–PCR analysis with the forward primer VctF, speciﬁc for the target
minigene and the PTM-speciﬁc reverse primer FLAGR, complementary to
the FLAG epitope sequence, demonstrates trans-splicing between minigene
transcripts and PTMs. The difference in size between the products generated
using Tau PTM6 and TauPTM9 corresponds to E10. (B) Change in E10
inclusion after co-transfection of LI9/LI10 with TauPTM6 and TauPTM9.
Both cis- and trans-spliced products were detected by RT–PCR with the
forward primer VctF and the reverse primer 11R, corresponding to an exon
11 sequence. Co-transfection with TauPTM6 or TauPTM9 resulted in an
increase or decrease of E10 inclusion, respectively.
Figure 3. Splicing pattern of minigenes containing FTDP-17 mutations. (A)
Structure of the MAPT minigenes incorporating the exonic N279K and
D280K mutations or the intronic DDPAC þ14 mutation. The backbone mini-
gene, TauEx9-11, consists of tau exons 9–10–11 and 498 bp 50 and 264 bp 30
of intronic sequences ﬂanking E10. (B) Splicing was assayed by RT–PCR
using primers VctF and 11R in transfected COS cells. TauEx9-11
WT produces
mainly E10
þ RNA; the mutants minigenes, TauEx9-11
DDPAC and
TauEx9-11
N279K, produce exclusively E10
þ RNA, whereas TauEx9-11
D280K
produces an excess of E10
2 RNA. Arrows indicate the locations of the PCR
primers used to detect splice isoforms.
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These results show that E10 usage can be modulated in either
direction, irrespective of the cis-splicing fate on an individual
targeted pre-mRNA.
Trans-splicing reduction of E10 excess caused
by intronic MAPT mutations
FTDP-17 MAPT mutations affecting splicing are located in spli-
cingregulatoryelementsandmostproduce excessE10inclusion.
WeassessedwhetherthelevelofE10inclusionintauRNAcould
be reduced by trans-splicing in the context of FTDP-17
mutations.AsmutationsarewithinorclosetoE10,trans-splicing
assays with mutant targets were performed using the
TauEx9-11
WT minigene backbone, with minimal intronic
sequences ﬂanking E10 (19) (Fig. 3A). The sequence of the
exon10/intron10junctionpredictsastem-loopstructureregulat-
ing E10 splicing by protecting the 50 splice site. FTDP-17
mutations þ3t oþ16 destabilize the stem loop and enhance
E10 inclusion (14,15,19). Among these the þ14 DDPAC
mutation is one of the most potent at increasing E10 inclusion
(4). To conﬁrm that the þ14 mutation resulted in E10 excess in
mature tau RNA, tau splicing was compared between COS cells
transfected with the wild-type minigene, TauEx9-11
WT or the
TauEx9-11
DDPAC minigene, containing the þ14 mutation.
TauEx9-11
WT generated mostly E10




minigene produced exclusively E10
þ RNA (Fig. 3B).
To determine whether RNA lacking E10 could be generated
by trans-splicing from a target containing the þ14 mutation
COS cells were co-transfected with the TauEx9-11
DDPAC
minigene and TauPTM9 and analyzed for occurrence of trans-
splicing and levels of E10 inclusion using the VctF-FLAGR or
VctF-11R primer combinations. Trans-splicing was ﬁrst con-
ﬁrmed for the wild-type minigene, TauEx9-11
WT, and Tau
PTM6 or TauPTM9 (Fig. 4A, B). Analysis of cells
co-transfected with the TauEx9-11
DDPAC minigene and
TauPTM6 or TauPTM9 demonstrated trans-splicing between
transcripts from the minigene and either PTM (Fig. 4C). In
the absence of PTM, the TauEx9-11
DDPAC minigene produced
E10
þ RNA only. In contrast, products lacking E10 were gen-
erated in cells co-transfected with TauPTM9 (Fig. 4D). Based
on the reduction in the percentage of E10 inclusion estimated
by semi-quantitative PCR, restoration of E10
2 RNA was
achieved with a 11% efﬁciency. The generation of E10
2
RNA is not the consequence of a direct change in cis-splicing
activity secondary to the blocking of a potential splicing
enhancer in intron 9 by the binding of the PTM as such pro-
ducts were not observed with TauPTM6 which has the same
binding domain as TauPTM9 (Fig. 4D).
Figure 4. Trans-splicing reduction of E10 inclusion in tau transcripts with the intronic þ14 mutation. COS cells were co-transfected with a wild-type tau mini-
gene, TauEx9-11
WT (A and B) or the TauEx9-11
DDPAC minigene containing the þ14 mutation (C and D) and TauPTM6 or TauPTM9 and analyzed by RT–PCR.
(A and C) PCR analysis with primers VctF and FLAGR demonstrates trans-splicing between minigene transcripts and PTMs. (B and D) E10 usage after
co-transfection with the minigenes was analyzed by RT–PCR using the VctF–11R primer combination. (B) Co-transfection of TauEx9-11
WT with
TauPTM9 reduced E10 inclusion. (D) The TauEx9-11
DDPAC minigene produces E10
þ RNA only and E10
2 products were generated after co-transfection
with TauPTM9. Co-transfection with TauPTM6 had no effect on E10 inclusion.
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was the result of recombination events at the DNA level
between minigene and PTM PCR analysis was conducted
with or without reverse transcription and with an extension
time sufﬁcient to amplify potential recombination products.
No trans-splicing (Fig. 5A) or cis- and trans-splicing
(Fig. 5B) products were detected when the reverse transcrip-
tion step was omitted. In addition, no large size species that
would have been indicative of recombination were ampliﬁed
from the traces of DNA present in the RNA preparation
using the VctF-FLAGR primer combination (Fig. 5A). In con-
trast minigene DNA was readily detected using the VctF-11R
primer combination (Fig. 5B). Therefore E10 can be skipped
by trans-splicing in the presence of a constitutively available
50 splice site in the target.
Trans-splicing reduction of E10 excess caused by exonic
MAPT mutations
The N279K mutation is located within an exonic splicing
enhancer (ESE) in E10, and increases E10 inclusion by facil-
itating the use of the 30 splice site of intron 9 (16,20). In trans-
fected cells, a minigene carrying the N279K mutation,
TauEx9-11
N279K, produces exclusively E10
þ RNA (Fig. 3B).
COS cells were co-transfected with the TauEx9-11
N279K mini-
gene and analyzed for occurrence of trans-splicing and levels
of E10 inclusion, as earlier. Analysis with the VctF and
FLAGR primers demonstrated trans-splicing between tran-
scripts from the TauEx9-11
N279K minigene and both
TauPTM6 and Tau PTM9 (Fig. 6A). Co-transfection of
TauEx9-11
N279K with TauPTM9 resulted in the appearance
of E10
2 products with a 7% efﬁciency, whereas
co-transfection with TauPTM6 had no effect (Fig. 6B).
The ESE strengthened by the N279 mutation is weakened
by the D280K deletion, causing reduced E10 inclusion (16).
In transfected cells, an excess of E10
2 RNA is produced
from a minigene containing the D280K mutation,
TauEx9-11
D280K (Fig. 3B). RT–PCR analysis demonstrated
trans-splicing between TauEx9-11
D280K transcripts and either
TauPTM6 or Tau PTM9 and a resulting increase or decrease
in the level of E10 inclusion, respectively (Fig. 6C, D).
Taken together, these results show that E10 usage can be
modulated by trans-splicing independently of the strength of
the cis-regulatory elements in the targets.
DISCUSSION
In this study, we have demonstrated that aberrant tau E10 spli-
cing resulting from FTDP-17 mutations can be partially cor-
rected by trans-splicing. We showed previously that
cis-splicing exclusion of E10 could be by-passed by trans-
splicing and that E10
2 to E10
þ tau RNA conversion could
be achieved from wild-type tau sequences (13). The demon-
stration that E10 inclusion can be reduced as well as increased
by trans-splicing shows that trans-splicing can occur irrespec-
tive of the outcome of the cis-splicing event determined by the
combination of splicing factors recruited by an individual
pre-mRNA. Importantly, correction of aberrant splicing
caused by FTDP-17 mutations shows that trans-splicing can
be achieved in the presence of cis-splicing elements of
altered strength.
Most intronic FTDP-17 mutations are clustered at the exon
10–intron 10 junction. This region is predicted to form a stem-
loop structure regulating E10 splicing by protecting the 50
splice site. FTDP-17 mutations þ3t oþ16, as well as the
exonic S305N mutation, destabilize the stem loop making
the 50 splice site of intron 10 constitutively available, hence
promoting E10 inclusion (14,15,20). E10 retention results in
a 1.5- to 6-fold increase in the E10
þ/E10
2 ratio (4,9). Trans-
splicing was achieved using a target carrying the very potent
DDPAC þ14 mutation and produced mature RNA lacking
E10 demonstrating that the constitutive availability of the 50
splice site of intron 10 does not interfere with trans-splicing.
The N279K mutation, within E10, strengthens an ESE and
facilitates the use of the 30 splice site of intron 9. The afﬁnity
of the splicing factors, Tra2b and SF2/ASF, for the ESE is
enhanced by the N279K mutation and, conversely, Tra2b
and SF2/ASF afﬁnity for the ESE is reduced by the D280K
deletion (16,17,21). The D280K mutation is the only known
MAPT mutation that reduces E10 inclusion and is associated
with lesions containing exclusively, or, at least predominantly,
3R tau (22,23). Trans-splicing obtained with the N279K
mutation and subsequent production of RNA lacking E10
shows that enhanced availability of the 30 splice site of
intron 9 in the target does not interfere with the use of the
30 splice site from the PTM, which is required for the trans-
splicing reaction. Therefore abnormal binding of Tra2b and/
or SF2/ASF to the ESE within the target does not inhibit trans-
splicing modulation of E10 usage in either direction. However,
its efﬁciency might be inﬂuenced by the interplay between
trans-acting factors recruited on the target and on the PTM.
The possibility of correcting E10 inclusion is relevant not
only for FTDP-17 but also for sporadic tauopathies. A single
molecule analysis of tau isoforms in Alzheimer’s disease
brain revealed an increase to 1.3 in the E10
þ/E10
2 ratio (24).
In addition, the H1 haplotype of the MAPT gene, which is
associated with an increased risk of Alzheimer’s disease,
expressesmoreE10
þtaumRNAthantheH2haplotype(25,26).
Several chemical inhibitors of E10 inclusion have been
identiﬁed through high throughput screening and could
Figure 5. Absence of recombination between minigene and PTM at the DNA
level. RNA isolated from cells co-transfected with TauEx9-11
DDPAC and
TauPTM6 or TauPTM9 was analyzed by PCR with (þRT) or without (2RT)
prior reverse transcription. No cis- or trans-splicing (A and B) products were
detected without RT. (A) Trans-splicing products only are ampliﬁed using the
VctF-FLAGR primer combination; no larger size species were detected with
or without RT. (B) In contrast, in addition to cis- and trans-splicing products,
minigene DNA was readily ampliﬁed from the traces of DNA present in the
RNA preparation using the VctF–11R primer combination.
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are gaining increasing popularity due to their speciﬁcity and
versatility (29). Among those, SMaRT has proved to be a
very powerful method to correct loss-of-function mutations
at the RNA level (30–33). Recent applications have included
correction of b-globin in sickle-cell anemia and b-thalassemia
(34), plectin (PLEC1) in blistering skin disease epidermolysis
bullosa simplex with muscular dystrophy (EBS-MD) (35),
severe combined immune deﬁciency (SCID) (36), spinal mus-
cular atrophy (37,38) and myotonic dystrophy (39). Gene
therapy for brain diseases is still at an early stage, but
several classes of viral vectors have been developed for the
transduction of neurons (40,41). Furthermore, long-term
expression of trans-splicing molecules obtained using viral
vectors or transposon systems has been shown to result in
recovery of functional defects compatible with a therapeutic
beneﬁt (36,38,42–44). The level of tau E10 splicing correction
necessary for a detectable phenotypic effect is not known,
neither is the precise consequence of tau isoform imbalance
on microtubule properties and functions or on neurotoxicity.
Trans-splicing reduction of E10 inclusion on endogenous tau
could be optimized in induced pluripotent stem cells derived
from FTDP-17 patients, when available, after differentiation
into neurons (45).
An increasing number of neurological and other disorders
are being associated with aberrant alternative splicing (46–
49) and SMaRT would be an approach to be developed to




The pre-trans-splicing molecule, TauPTM6, in the mamma-
lian expression vector, pcDNA3.1, has been described pre-
viously (13). TauPTM6 is designed to include E10 in tau
RNA; its coding sequence consists of tau exons 10–13, fol-
lowed by a FLAG epitope sequence (50-GACTACAAGG
ACGACGATGACAAG-30). TauPTM9, designed to exclude
E10 from tau RNA, was generated by deleting E10
from TauPTM6, using restriction digestions and ligation of
synthetic oligonucleotides.
Tau minigene targets
The LI9/LI10 minigene in the pCIneo vector comprises tau
exons 9–10–11 and full-length introns 9 and 10 (18) and
was obtained from Dr Jianhua Zhou (University of Massachu-
setts Medical School, Worcester). Minigenes TauEx9-11
WT
and TauEx9-11
DDPAC comprising tau exons 9–10–11 and
498 bp of 50 and 264 bp 30 of intronic sequences ﬂanking
E10 (19) (Fig. 3) were obtained from Dr Jane Wu (Northwes-
tern University Feinberg School of Medicine, Chicago).
Figure 6. Trans-splicing modulation of E10 usage in tau transcripts with the exonic N279K and D280K mutations. COS cells were co-transfected with the
TauEx9-11
N279K (A and B) or the TauEx9-11
D280K (C and D) tau minigenes and TauPTM6 or TauPTM9 and analyzed by RT–PCR. (A and C) PCR analysis
with primers VctF–FLAGR demonstrates trans-splicing between minigene transcripts and PTMs. (B and D) E10 usage after co-transfection with the minigenes
was analyzed by RT–PCR using the VctF-11R primer combination. (B) Co-transfection of TauEx9-11
N279K with TauPTM9 resulted in the appearance of E10
2
products. Co-transfection with TauPTM6 had no effect on E10 inclusion. (D) The TauEx9-11
D280K minigene produces both E10
þ and E10
2 RNA, with a slight
excess of E10
2 RNA. Co-transfection with TauPTM6 or TauPTM9 increased or reduced E10 inclusion, respectively.
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DDPAC minigene carries the intronic þ14
DDPAC FTDP-17 mutation. Two additional minigenes,
TauEx9-11
N279K and TauEx9-11
D280K were constructed by
introducing the exonic N279K and D280K mutations into
TauEx9-11 using the Quick-Change site-directed mutagenesis
kit (Stratagene). Wild-type and mutant minigenes based on
TauEx9-11 were subcloned into pCIneo. All constructs were
veriﬁed by sequencing.
Cell culture and transfection
COS-7 cells were maintained in DMEM supplemented with
10% (v/v) heat inactivated FBS (Invitrogen), 100 U/ml peni-
cillin/100 mg/ml streptomycin and 2 mML -glutamine, in a
humidiﬁed atmosphere of 95% air/5% CO2 at 378C. Cells
were transfected with Lipofectamine 2000 reagent (Invitro-
gen). Brieﬂy, cells plated on 35 mm dishes were grown to
60–70% conﬂuency and exposed to the DNA/liposome
complex for 5 h in Optimem (Invitrogen) before being
returned to normal culture medium. Cells were routinely ana-
lyzed 24 h after transfection. Cells were transfected with either
tau minigene plus empty vector or PTM plus empty vector, or
co-transfected with minigene and PTM. Typically, 2 mg mini-
gene and 2 mg PTM were used in each transfection.
RT–PCR analysis of cis- and trans-splicing
Total RNA was isolated from transfected cells using Trizol
reagent (Invitrogen). Reverse transcription was performed
using the MultiscribeTM RT kit (Applied Biosystem) and
oligo-(dT)16. Reverse transcription was carried out under the
following conditions: 10 min at 258C, 30 min at 488C and a
ﬁnal step of 5 min at 958C. Reverse transcribed RNA was
ampliﬁed by using Go Taq polymerase (Promega) under the
following conditions: 948C for 5 min, 30 cycles of 1 min at
948C, 1 min at 588C, 1 min at 728C and a ﬁnal step of
10 min at 728C. An extension time of 3 min was used in reac-
tions designed to visualize DNA. The sequence of the primers
used for PCR and the sizes of cis- and trans-splicing products
are listed in Table 1. PCR products were separated by electro-
phoresis in 2% (w/v) agarose gels and stained with ethidium
bromide. Densitometric analysis of triplicate experiments
was performed using the Innotech software (Alpha Innotech,
San Leandro, CA, USA). Splicing activity was expressed as
percentage of E10 inclusion. The efﬁciency of E10
þ to
E10
2 conversion was estimated from the percentage of E10
inclusion in cells transfected with minigene only (p1) and
co-transfected with minigene and PTM (p2) as 100  
(p12p2)/p1. For sequencing, PCR products were excised
from agarose gels and cloned into the pCR2.1 vector using
the TA cloning system (Invitrogen). Sequencing of both
strands was performed using T3 and T7 primers.
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